• EnglishEnglish
    • Deutsch Deutsch
    • Italiano Italiano
    • Français Français
    • 日本語 日本語
    • 한국어 한국어

CISEMA - China Zertifizierung, Einkauf und Qualitätssicherung

  • Services
    • NMPA Registration – Medical Devices and IVDs
    • NMPA Registration & DMF – Pharmaceuticals
    • NMPA Registration – Cosmetics
    • NMPA Registration – Health Food
    • CML (China Manufacture Licence) – Pressure vessels
    • CCC (China Compulsory Certification) – Industrial and consumer goods
    • Others
      • Sourcing and Quality Control
      • Logistics and Customs Support
      • Sales Support
  • Events
    • Trade Fairs & Conferences
    • Seminars
    • Webinars
  • News & Knowledge
    • Regulatory News
      • Medical Devices and IVDs
      • Cosmetics
      • Pharmaceuticals & DMF
      • CCC
      • Pressure Vessels
    • Whitepapers
    • FAQ – NMPA Registration – Medical Devices and IVDs
    • Newsletter Sign Up
    • Others
      • Publications
      • Online Shop
  • About us
    • Partners
    • Company Profile
    • Testimonials
  • Locations
  • Newsletter Sign Up
Contact
  • Home
  • News
  • News
  • NMPA Registration in China
  • Medical Device
  • NMPA Initiates Regulation of Nanomaterials in Medical Devices

NMPA Initiates Regulation of Nanomaterials in Medical Devices

Tuesday, 28 September 2021 / Published in Medical Device, News, NMPA Registration in China

NMPA Initiates Regulation of Nanomaterials in Medical Devices

On August 26, 2021, the NMPA (National Medical Products Administration) published (No.65-2021) Part I of the Technical Guidelines for the Evaluation of Safety and Effectiveness of Nanomaterials in Medical Devices: System Framework.

Definition of Nanomaterials

According to the national standard GB/T30544.1, nanomaterials are materials with any external dimension, internal or surface structure at the nanoscale with the size range between 1 nm and 100 nm. The properties of the nanomaterials should be unique and not be found in larger sized particles at the macroscopic scale or out of the nanoscale range.

Scope

The guidelines are applicable to:
 – The evaluation of the safety and efficacy of medical devices that come into direct or indirect contact with the human body and that consist of or contain nanomaterials.
The guidelines are not applicable to:
– In Vitro Diagnosis (IVD) products that apply nanomaterials, but may be relevant when considering the effectiveness of IVD products.
– Enabling technologies for the application of nanomaterials.
– Pharmaceutical products with applications of nanomaterials.
– Occupational and environmental risks posed by medical devices applying nanomaterials during manufacture and disposal.

Highlights

Applicants should confirm the suitability of the test system by designing a series of tests to establish a biological evaluation test protocol that is suitable for the characteristics of the declared product.

The following potential risks should be taken into account:

  • The possibility of free nanoparticles released from the device
  • The dosage number of free nanoparticles released
  • The duration of the release of free nanoparticles
  • The route of contact with the body and which part of the body the free nanoparticles were exposed to.
  • Even if the medical device does not contain nanomaterials, the wear and tear itself can create nanoscale particles.

The guidelines may also be applicable to medical devices that contain particles with the size bigger than 100 nm that may possess different properties and safety risks.

There are four major steps during the risk evaluation process:

  1. Evaluate the possibility of nanoparticles released directly or due to wear and tear of the device
  2. Particle distribution and persistence
  3. Hazard assessment (Biological/toxicological evaluations)
  4. Risk assessment

According to the guidelines, the applicants may also consider to collect post-market real-world data that will help reflect the benefits and risks of the devices, and develop risk control measures.

This is the first set of guidelines in China published specifically for nanomaterials used in medical devices in China, and we expect more developments on the respective regulatory framework announced in the near future.

By Dora Yang and Jacky Li. Contact Cisema if you would like to learn more.

Tagged under: nanomaterials

What you can read next

China cosmetics ingredient safety information platform
China cosmetics ingredient safety information platform guidelines
New Medical Device Classification Catalogue in Draft
Hainan Communication SOP
Hainan Communication SOP for Medical Device Clinical RWD Applications (Trial)

Search

Categories

  • Fairs & Events
  • News
    • CCC
    • CEL
    • CML, SELO
    • Medical Devices Listing in Hong Kong
    • NMPA Registration in China
      • Cosmetics
      • Health Food
      • Medical Device
      • Pharmaceuticals & DMF
    • RoHS
    • Voluntary Product Certification
  • Publications
  • Registration of Pharmaceuticals in Hong Kong
  • Seminars
  • Uncategorized
  • Webinars

Recent Posts

  • china power switchgear control gear assemblies standard update

    China power switchgear and control gear assemblies standard GB/T 7251 update

    China power switchgear and control gear assembl...
  • China medical device supervision inspection results

    China medical device supervision inspection results

    China medical device supervision inspection res...
  • China toothpaste filing requirements

    China Toothpaste Filing Requirements

    China Toothpaste Filing Requirements were issue...
  • Building Successful China Medtech Market Entry Strategies

    Webinar | Building Successful China Medtech Market Entry Strategies – From the Market Access Perspective

    Building successful China Medtech market entry ...
  • China cosmetic regulatory violation

    China cosmetic regulatory violation cases reported by the NMPA

    China cosmetics regulatory violation cases were...

Archive

Cisema

With twelve locations and over ninety highly qualified employees, Cisema can offer you optimal support in China.

Services

  • Certification
  • Sourcing and Quality Control
  • Logistics and Customs Support
  • Sales Support

Dialogue

  • Contact us
  • Newsletter Signup
  • Events
  • News & Knowledge
  • Partners

Company

  • GTC
  • Privacy Statement
  • Legal Notice
  • About us
  • Locations
  • GET SOCIAL

© 2003-2023 Cisema. All rights reserved.

TOP